CR10818A - Inhibidores de cinasa mapk/erk - Google Patents

Inhibidores de cinasa mapk/erk

Info

Publication number
CR10818A
CR10818A CR10818A CR10818A CR10818A CR 10818 A CR10818 A CR 10818A CR 10818 A CR10818 A CR 10818A CR 10818 A CR10818 A CR 10818A CR 10818 A CR10818 A CR 10818A
Authority
CR
Costa Rica
Prior art keywords
erk
mapk
cinase
inhibitors
cinase inhibitors
Prior art date
Application number
CR10818A
Other languages
English (en)
Inventor
Qing Dong
Victoria Feher
Stephen W Kaldor
Naoki Tomita
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR10818A publication Critical patent/CR10818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Se proporcionan compuestos, composiciones farmaceuticas, kits y metodos para uso con MEK, que comprenden un compuesto seleccionado del grupo que consiste de: en donde las variables son como se definen en la presente.
CR10818A 2006-10-23 2009-05-21 Inhibidores de cinasa mapk/erk CR10818A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86256906P 2006-10-23 2006-10-23

Publications (1)

Publication Number Publication Date
CR10818A true CR10818A (es) 2009-07-07

Family

ID=39954277

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10818A CR10818A (es) 2006-10-23 2009-05-21 Inhibidores de cinasa mapk/erk

Country Status (25)

Country Link
US (4) US20100204471A1 (es)
EP (1) EP2091941B1 (es)
JP (1) JP5249939B2 (es)
KR (1) KR20090071666A (es)
CN (1) CN101563338A (es)
AR (1) AR063357A1 (es)
AU (1) AU2007353385A1 (es)
BR (1) BRPI0717374A2 (es)
CA (1) CA2667447A1 (es)
CL (1) CL2007003041A1 (es)
CO (1) CO6180442A2 (es)
CR (1) CR10818A (es)
DO (1) DOP2009000089A (es)
EA (1) EA200970407A1 (es)
EC (1) ECSP099354A (es)
IL (1) IL198254A0 (es)
MA (1) MA30889B1 (es)
MX (1) MX2009004269A (es)
NO (1) NO20091999L (es)
NZ (1) NZ577047A (es)
PE (1) PE20081468A1 (es)
TN (1) TN2009000151A1 (es)
TW (1) TW200831100A (es)
WO (1) WO2008140553A2 (es)
ZA (1) ZA200903274B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007353385A1 (en) * 2006-10-23 2008-11-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
US8022057B2 (en) * 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
US8980254B2 (en) 2008-08-21 2015-03-17 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
WO2013151877A1 (en) * 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinedione carboxamide inhibitors of endothelial lipase
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
DE102015117207A1 (de) 2015-10-08 2017-04-13 Silas Mehmet Aslan Verfahren zur Herstellung von polythiophenhaltigen Fluiden
IL259810A (en) 2018-06-04 2018-07-31 Yeda Res & Dev Mitogen-activated protein kinase kinase 7 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58152890A (ja) * 1982-03-08 1983-09-10 Takeda Chem Ind Ltd イソキサゾロピリミジン誘導体
US6251943B1 (en) 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
ES2274572T3 (es) 1997-07-01 2007-05-16 Warner-Lambert Company Llc Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
WO1999001426A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
AU2001273498B2 (en) 2000-07-19 2006-08-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2005000818A1 (en) * 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
AU2004293019B2 (en) * 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
CA2587178A1 (en) 2004-11-24 2006-06-01 Laboratoires Serono S.A. Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
US20060223807A1 (en) * 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Ｍｅｋ雜環抑制劑及其使用方法
AU2007353385A1 (en) * 2006-10-23 2008-11-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
US8022057B2 (en) 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
CL2007003041A1 (es) 2008-03-24
AU2007353385A1 (en) 2008-11-20
US20100113413A1 (en) 2010-05-06
CN101563338A (zh) 2009-10-21
AR063357A1 (es) 2009-01-21
EA200970407A1 (ru) 2009-12-30
CA2667447A1 (en) 2008-11-20
PE20081468A1 (es) 2008-12-03
WO2008140553A3 (en) 2009-02-26
NZ577047A (en) 2011-02-25
BRPI0717374A2 (pt) 2013-10-29
DOP2009000089A (es) 2010-03-31
WO2008140553A4 (en) 2009-04-30
TW200831100A (en) 2008-08-01
US20100204471A1 (en) 2010-08-12
MX2009004269A (es) 2009-08-12
JP5249939B2 (ja) 2013-07-31
US20110190261A1 (en) 2011-08-04
US7943626B2 (en) 2011-05-17
TN2009000151A1 (en) 2010-10-18
CO6180442A2 (es) 2010-07-19
US7696218B2 (en) 2010-04-13
WO2008140553A2 (en) 2008-11-20
IL198254A0 (en) 2009-12-24
US20080125437A1 (en) 2008-05-29
JP2010507683A (ja) 2010-03-11
ECSP099354A (es) 2009-06-30
US8088783B2 (en) 2012-01-03
EP2091941B1 (en) 2013-01-23
EP2091941A2 (en) 2009-08-26
KR20090071666A (ko) 2009-07-01
MA30889B1 (fr) 2009-11-02
NO20091999L (no) 2009-07-06
ZA200903274B (en) 2010-08-25

Similar Documents

Publication Publication Date Title
ECSP099354A (es) Inhibidores de cinasa mapk/erk
CR10937A (es) Inhibidores de cinasa mapk/erk
UY32049A (es) Inhibidores de cmet
CR20110223A (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGÍA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
CR9664A (es) Inhibidores de histona deacetilasa
WO2008055236A3 (en) Mapk/erk kinase inhibitors
CO6220968A2 (es) Inhibidores heterociclicos de la aspartil proteasa
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ATE479687T1 (de) Kinaseinhibitoren
BR112013021896A2 (pt) inibidores de serina/treonina cinase
WO2008115890A3 (en) Mapk/erk kinase inhibitors
ECSP10010688A (es) Activadores de glucoquinasa
BRPI0803374A2 (pt) compostos polihidróxi como agentes de extinção de polimerização
CR11492A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
CR11370A (es) Inhibidores de quinasas simil polo
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
CR10780A (es) Inhibidores de cinasa
UY30488A1 (es) Bencilaminas,un proceso para su produccion y su uso como agentes anti-inflamatorios.
GT200300046A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
NI201100035A (es) Agentes antifúngicos.
AR075301A1 (es) Composicion y metodo para controlar enfermedades de plantas
AR102866A1 (es) Composiciones y métodos para la introducción de micronutrientes
AR072426A1 (es) Uso de nifurtimox para el tratamiento de enfermedades causadas por tricomonadida
CO6331464A2 (es) Inhibidores de cinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)